Population pharmacokinetics of micafungin in adult patients

被引：63

作者：

Gumbo, Tawanda ^{[1
]}

Hiemenz, John ^{[2
]}

Ma, Lei ^{[1
]}

Keirns, James J. ^{[3
]}

Buell, Donald N. ^{[3
]}

Drusano, George L. ^{[1
]}

机构：

[1] Ordway Res Inst, Albany, NY 12208 USA

[2] Feist Weiller Canc Ctr, Shreveport, LA 71130 USA

[3] Astellas Pharma USA Inc, Deerfield, IL 60015 USA

来源：

DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE | 2008年 / 60卷 / 03期

关键词：

micafungin; population pharmacokinetics;

D O I：

10.1016/j.diagmicrobio.2007.09.018

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

We performed population pharmacokinetic analysis of micafungin in adult patients treated with doses between 12.5 and 200 mg/day. Our analysis identified a breakpoint patient weight of 66.3 kg above which serum clearance increased by approximately 50%. Patients with weight >66.3 kg may need larger doses to achieve similar exposures to those <66.3 kg. However, the clinical implications are still unknown. (c) 2008 Elsevier Inc. All rights reserved.

引用

收藏

页码：329 / 331

页数：3

相关论文

共 12 条

[1] NEW LOOK AT STATISTICAL-MODEL IDENTIFICATION [J].

AKAIKE, H .

IEEE TRANSACTIONS ON AUTOMATIC CONTROL, 1974, AC19 (06) :716-723

[2]

*AST PHARM INC, 2005, PACK INS MYC

[3] Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis [J].

Denning, David W. ;

Marr, Kieren A. ;

Lau, Wendi M. ;

Facklam, David P. ;

Ratanatharathorn, Voravit ;

Becker, Cornelia ;

Ullmann, Andrew J. ;

Seibel, Nita L. ;

Flynn, Patricia M. ;

van Burik, Jo-Anne H. ;

Buell, Donald N. ;

Patterson, Thomas F. .

JOURNAL OF INFECTION, 2006, 53 (05) :337-349

[4] Population pharmacokinetic analysis of anidulafungin, an echinocandin antifungal [J].

Dowell, JA ;

Knebel, W ;

Ludden, T ;

Stogniew, M ;

Krause, D ;

Henkel, T .

JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 44 (06) :590-598

[5] Once-weekly micafungin therapy is as effective as daily therapy for disseminated candidiasis in mice with persistent neutropenia [J].

Gumbo, Tawanda ;

Drusano, George L. ;

Liu, Weiguo ;

Kulawy, Robert W. ;

Fregeau, Christine ;

Hsu, Vasha ;

Louie, Arnold .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2007, 51 (03) :968-974

[6] Pharmacokinetic and maximum tolerated dose study of micafungin in combination with fluconazole versus fluconazole alone for prophylaxis of fungal infections in adult patients undergoing a bone marrow or peripheral stem cell transplant [J].

Hiemenz, J ;

Cagnoni, P ;

Simpson, D ;

Devine, S ;

Chao, N ;

Keirns, J ;

Lau, W ;

Facklam, D ;

Buell, D .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (04) :1331-1336

[7]

LEARY R, 2001, ADAPTIVE NONPARAMETR

[8] Prevalence of overweight and obesity in the United States, 1999-2004 [J].

Ogden, CL ;

Carroll, MD ;

Curtin, LR ;

McDowell, MA ;

Tabak, CJ ;

Flegal, KM .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (13) :1549-1555

[9] International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia [J].

Ostrosky-Zeichner, L ;

Kontoyiannis, D ;

Raffalli, J ;

Mullane, KM ;

Vazquez, J ;

Anaissie, EJ ;

Lipton, J ;

Jacobs, P ;

van Rensburg, JHJ ;

Rex, JH ;

Lau, W ;

Facklam, D ;

Buell, DN .

EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2005, 24 (10) :654-661

[10] Comparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits [J].

Petraitis, V ;

Petraitiene, R ;

Groll, AH ;

Roussillon, K ;

Hemmings, M ;

Lyman, CA ;

Sein, T ;

Bacher, J ;

Bekersky, I ;

Walsh, TJ .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (06) :1857-1869